ico KO
menu_bt
close_bt
img
ico KO
menu_bt
close_bt
THE ENTEROBIOME

WHAT WE DO

WHAT WE DO

WHAT WE DO

BUSINESS AREA FOR MICROBIOME
img1
  • STEP 01
    Metabolic Disease
    • Medicine (Obesity, NASH)
    • Health functional food
      (diabetes)
    • Single strainarrowCocktail
  • arrow
  • STEP 02
    Application expansion
    • Immune disease
      (Atopy, Asthma), Cancer, etc.
    • cGMP production plant
      (23’ – 25’)
  • arrow
  • STEP 03
    Microbiome Analysis
    • Big data construction /
      application
    • Customized product
We plan to construct our own cGMP grade plant for
manufacturing microbiome products in Korea by 2025
  • img2
    Secured library of new drug candidates from microbiome strains

    Global class : core microbiome strains in possession

    • - Akkermansia muciniphila
    • - Anaerostipes caccae
    • - Bacteroides uniformis
    • - Faecalibacterium prausnitzii
    • - Eubacterium rectale
    • - Bacteroides thetaiotaomicron

    Construction of extreme anaerobic human microbiome library in addition to the above 6 species

  • img3
    Establishment of mass production basis for new drug production

    Achievement of cultivation solution optimization and patent registration

  • img4
    Production of proto-type microbiome drug product for global clinical study